Latest Asia Pacific News

Bluechiip Limited reported a $221,000 net cash outflow for Q2 FY2025, with cash reserves dwindling to $121,000. The company has initiated a strategic review and plans a capital raise to secure its future.

Unith Ltd has reported its strongest quarterly revenue in two years, driven by its B2C subscription division and strategic partnerships, while advancing its Digital Human technology and expanding into new markets.

VRX Silica Limited has achieved a major milestone with the EPA recommending approval for its Arrowsmith North Silica Sand Project, alongside securing $5 million in capital and expanding offtake agreements.

Opyl Limited's Q2 FY25 update reveals robust progress through key partnerships, a new AI Biotech Fund launch, and strengthened financial footing, positioning the company for expanded influence in clinical trial optimisation.

DroneShield has secured three contracts worth $11.8 million from an Asia Pacific military customer, signaling growing adoption of its counter-drone technology in the region.

Algorae Pharmaceuticals reports robust progress in its drug development pipeline, highlighted by promising preclinical results for cardiovascular and dementia candidates and significant AI platform enhancements.

Monadelphous Group Limited signals a stronger-than-expected half-year profit, driven by improved operating margins and favourable non-operating items.

SomnoMed reports a robust 19.8% revenue increase in Q2 FY25 and updates its full-year guidance, reflecting strong demand and operational improvements amid ongoing production enhancements.

Memphasys Limited marks a pivotal quarter with the completion of clinical trials for its Felix™ System, strategic market expansions in Greater China and the Middle East, and a successful capital raise to fuel growth.

Santos delivered a robust Q4 2024 with over US$1.4 billion in sales revenue and strong free cash flow, while progressing key LNG projects and expanding its decarbonisation initiatives.

EZZ Life Science Holdings delivered a robust Q2 FY25 with a 16.6% increase in customer receipts and a 308% jump in operating cash flows, while gearing up for US market entry and expanding its global footprint.

Icetana Limited reports a challenging December quarter with declining revenues but secures significant new contracts and launches a fully underwritten $2.65 million rights issue.